PDCD1 and myeloproliferative disorder: Although this clinical trial on the efficacy of PD-1 blockade using the monoclonal antibody Nivolumab was prematurely terminated due to a lack of efficacy, more clinical studies are currently ongoing to evaluate if ICB could be a promising therapeutic option in MPN patients (Table 4).